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Introduction: Positive responses to bronchodilators (BDs) on spirometry can be found in up to
30% of patients with lymphangioleiomyomatosis (LAM). However, no previous studies have
investigated the impact of BDs on exercise outcomes, including dynamic hyperinflation (DH).
Methods: A randomised, double-blind, placebo-controlled, crossover trial was conducted on 38
patients with LAM, comparing inhaled placebo versus salbutamol. Pulmonary function tests
and a cycle endurance test at 75% of the maximal work capacity, with evaluation of DH by se-
rial measurement of inspiratory capacity (IC), which was the primary endpoint, were per-
formed after each intervention.
Results: Although salbutamol produced a slight improvement in airway obstruction, compared
with placebo, there was no significant variation in resting IC or air trapping. A total of 18% of
the patients met the criteria for a positive response to BD. During submaximal exercise, BD did
not reduce DH or dyspnoea nor did it improve exercise tolerance in the entire population. In
addition, BD produced only slight improvement in FEV1 and air trapping in patients who had
DH during incremental cardiopulmonary exercise testing, without the beneficial effects on
exercise outcomes.
Conclusions: Although salbutamol produced a slight improvement in airway obstruction, it did
not lead to a reduction in DH or increase in exercise tolerance in patients with LAM.
Clinical trial registration: Brazilian Registry of Clinical Trials (ReBEC); www.ensaiosclinicos.
gov.br; registration number: RBR-49sk2j.
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1774 B.G. Baldi et al.Introduction informed consent form was obtained from all patients. TheLymphangioleiomyomatosis (LAM) is a rare disease that
mainly affects women of childbearing age and is charac-
terised by peribronchial, perivascular and lymphatic pro-
liferation of abnormal muscle cells (LAM cells), which can
lead to vascular and airway obstruction and cyst formation
[1]. The pulmonary function tests (PFTs) in LAM are char-
acterised by an obstructive pattern, air trapping and
reduced diffusion capacity of the lung for carbon monoxide
(DLCO) [2e5]. The prevalence of positive response to
bronchodilators (BDs), which is characterised by changes in
forced expiratory volume in the first second (FEV1) and/or
forced vital capacity (FVC) of 12% and 200 mL over
baseline, according to American Thoracic Society/European
Respiratory Society (ATS/ERS) criteria, ranges from 6 to 30%
in LAM [3e8]. The pathophysiology of airflow limitation
involves increased resistance due to LAM cell proliferation
around the airways rather than changes in elastic recoil due
to connective tissue matrix destruction caused by the
imbalance between the activity of matrix metal-
loproteinases (MMPs) and their inhibitors in LAM lesions
[5,9,10].
Previous studies showed that reduced maximal work
load and oxygen consumption (VO2) are frequent in LAM;
although multiple mechanisms are responsible for exercise
limitation, it is mainly caused by ventilatory and gas ex-
change abnormalities [2,11e13]. Recently, we have shown
that the development of dynamic hyperinflation (DH) dur-
ing incremental cardiopulmonary exercise testing (CPET) is
common in patients with LAM, and is associated with the
severity of disease and augmented dyspnoea [2].
Despite the positive effects of BDs on spirometry in LAM,
none of these studies have investigated the effects of BDs
on air trapping, as measured by residual volume (RV) and
RV/TLC ratio (TLC, total lung capacity), or on exercise
outcomes, such as dyspnoea and exercise tolerance
[3e5,7,8]. Studies in COPD showed a poor correlation be-
tween increases in FEV1 and improvements in dyspnoea and
exercise performance after the administration of BDs,
which is also plausible for patients with LAM [14,15].
Therefore, the primary endpoint of this study was to
investigate the impact of the short-acting BD salbutamol on
reducing DH during a cycle endurance test exercise in pa-
tients with LAM, and to determine secondarily the impact
on PFTs, including reduction of air trapping, and if this
treatment would improve dyspnoea and exercise
performance.
Methods
Subjects
The study population comprised all patients diagnosed with
LAM based on the guidelines of the ERS and were enrolled in
the outpatient clinic of the Pulmonary Division of the Hos-
pital das Clinicas of the University of Sao Paulo [1]. The
study population comprised the same group evaluated in a
study recently published that showed a high prevalence of
DH and its repercussions in LAM [2]. The protocol was
approved by the local research ethics committee and theresearch protocol has been listed in the Brazilian Registry
of Clinical Trials, available at ensaiosclinicos.gov.br, under
the identification number RBR-49sk2j and follows dataset
requirements set forth by the International Committee of
Medical Journal Editors.
Patients were excluded if they used supplemental oxy-
gen, underwent lung transplantation, or had musculoskel-
etal disorders, heart disease or any other disabling
condition that could interfere with testing. Patients were
clinically stable for at least 6 weeks prior to the study.
Study protocol
This was a single-centre, randomised, double-blind, pla-
cebo-controlled, crossover trial. Patients were instructed
to discontinue all b2 agonists for 48 h before the submaxi-
mal exercises. The protocol was performed on 3 consecu-
tive days (1 visit every day).
At visit 1, patients underwent a clinical evaluation,
including a questionnaire of dyspnoea (Baseline Dyspnoea
Index, BDI), and data obtained in a recent incremental
CPET performed was reviewed [2]. In this incremental
CPET, patients performed a symptom-limited incremental
CPET on a cycle ergometer, from which the maximum
work rate was obtained. Before visit 2, patients were
randomised to 400 mcg salbutamol via a metered-dose
inhaler (Aerolin Spray, GlaxoSmithKline) or an identical
placebo [16]. The random allocation was balanced (1:1)
and performed by using 38 sealed envelopes containing
the first intervention (19 salbutamol and 19 placebo),
which was administrated by a blinded technician who did
not take part of the measurements. At visit 3, patients
crossed over to receive the alternative intervention. At
visits 2 and 3, 30 min after inhaling salbutamol or placebo,
patients performed PFTs and a cycle endurance test at
75% of the maximal work reached on the incremental
CPET (Fig. 1).
Measurements
Pulmonary function tests: Spirometry was performed using
a calibrated pneumotachograph (Medical Graphics Corpo-
ration, St. Paul, MN) and lung volumes and DLCO were ob-
tained with a body plethysmograph (Elite Dx, Elite Series;
Medical Graphics Corporation). The following variables
were obtained at visits 2 and 3 after each intervention:
FVC, FEV1, inspiratory capacity (IC), TLC, RV, and maximal
voluntary ventilation (MVV). DLCO was measured during visit
2. All measurements were made according to the ATS/ERS
recommendations, and predicted values were derived from
the Brazilian population [17e22].
Cardiopulmonary exercise test: CPETs were performed
using a cycle ergometer (Corival, Lode B.V.; Medical
Technology, The Netherlands). Oxygen saturation (SpO2), as
measured by pulse oximetry (Onyx, model 9500; Nonin,
Plymouth, MN), and electrocardiography (Welch Allyn Car-
dioPerfect, Inc., NY) were monitored continuously during
the tests. The following variables were recorded (CardioO2
System; Medical Graphics Corporation) breath-by-breath
and expressed as the average of the last 15 s of rest, of
Figure 1 Study design. Definition of abbreviations: PFTs: pulmonary function tests; CPET: cardiopulmonary exercise test.
Bronchodilator in lymphangioleiomyomatosis 1775each second minute during exercises and at the end of the
tests: work rate (WR), VO2, minute ventilation (VE), carbon
dioxide production (VCO2), tidal volume (VT), respiratory
rate (f), respiratory exchange rate (RER) and heart rate
(HR). Blood pressure, modified Borg scales for leg discom-
fort and dyspnoea, and IC manoeuvers were obtained at
rest, every 2 min during testing, and at the end of testing
[23]. In the incremental CPET whose data was reviewed at
visit 1, patients performed a ramp symptom-limited CPET
that consisted of 2 min of rest, a 2-min warm-up (unloaded
pedalling) and an incremental work-rate period (increase
from 10 to 20 W/min). DH was established during incre-
mental CPET based on an IC reduction of at least 10% from
baseline, assuming that TLC remained constant during ex-
ercise [2,24]. At visits 2 and 3, after inhalation of salbuta-
mol or placebo, the patients performed endurance exercise
tests. The protocol consisted of 2 min of rest, a 2-min
warm-up (unloaded pedalling) and a constant work-rate
period at 75% of the maximal WR reached on the incre-
mental CPET. Exercise (endurance) time was defined as the
duration of constant-loaded pedalling. To compare the re-
sponses between the endurance CPETs, a standardised ex-
ercise time (isotime) was established for each patient and
consisted of the point where the exercise with shorter
duration ended. The isotime in the test with the longer
duration was defined by rounding down to the nearest
minute of the isotime of the test with the shortest duration
where there were available data. All variables were
compared between endurance CPETs at isotime. Predicted
values for CPET were obtained from the Brazilian popula-
tion [25].Statistical analysis
The sample size of 28 patients provides the power (80%) to
detect a treatment difference in IC variation (isotime e
baseline) of 10%, a Z 0.05. Data are reported as the
mean  SD for variables with normal distribution or as the
median (25the75th percentiles) for variables with non-
normal distribution. Unpaired t-tests or the Man-
neWhitney U test were used to compare continuous vari-
ables between different groups. Paired t-tests or Wilcoxon
tests were used to compare within-subject results. A two-
way repeated measures ANOVA was performed to examine
the effect of interaction between treatment period and
intervention. Differences were considered significant if p
was less than 0.05. The data were analysed with SigmaStat
version 3.5 (Systat Software, Inc., San Jose, CA).Results
Population characteristics and incremental
cardiopulmonary exercise testing
Seven patients refused to participate in the study, and 10
out of 55 patients were excluded (6 because of their use
of supplemental oxygen, 2 due to their history of
arrhythmia with the use of BD, 1 because of joint disease
and 1 due to severe obesity). Then, 38 patients with LAM
were enrolled in the study: 6 patients (16%) were ex-
smokers, 23 (60%) had a history of pneumothorax, 6 (16%)
had a history of chylothorax, 5 (13%) had tuberous scle-
rosis, and 17 (45%) had a history of pleurodesis. The mean
age of the patients enrolled in the study was 41  10
years, and the median time from diagnosis was 27 months.
Only 1 patient was continuously using a long-acting b2
agonist. No patient was using inhaled corticosteroid or
rapamycin, whereas 12 patients were using doxycycline
and 13 were receiving hormonal therapy (gonadotropin-
releasing hormone agonist).
The general characteristics and data at peak of incre-
mental CPET are shown in Table 1. The patients experi-
enced mild dyspnoea for daily activities (BDI) and
diminished exercise performance (WR). DH occurred in 19
patients (50%) during incremental CPET.
Pulmonary function tests after placebo versus
salbutamol
After inhalation of salbutamol, there was a slight increase
in FEV1, with improvement in the degree of airflow
obstruction. However, there was no significant change in
resting IC or air trapping (RV and RV/TLC ratio) (Table 2).
Seven patients (18%) met the criteria for positive response
to BDs (changes in FEV1 and/or FVC of 12% and 200 mL
over baseline) [6]. No significant interaction effect be-
tween treatment period and intervention was demon-
strated for FEV1 (F Z 1.52; p Z 0.22).
Submaximal endurance exercise responses after
placebo versus salbutamol
Table 3 shows data from submaximal endurance exercise
tests after interventions. The endurance time in CPETs was
similar after inhalation of placebo and salbutamol. There
was also no difference in IC variation from baseline, thus
Table 2 Comparison of pulmonary function tests of pa-
tients with lymphangioleiomyomatosis after administration
of placebo or salbutamol.
Placebo
(n Z 38)
Salbutamol
(n Z 38)
P
FEV1, L 2.27  0.7 2.4  0.67 <0.001*
% predicted 79  23 84  22 <0.001*
FVC, L 3.27  0.58 3.32  0.59 0.08
% predicted 94  15 96  15 0.08
FEV1/FVC 0.73 (0.61e0.8) 0.78 (0.66e0.83) <0.001*
IC, L 2.29 (2.07e2.54) 2.3 (1.99e2.65) 0.52
% predicted 98  18 95  20 0.37
TLC, L 5.03 (4.54e5.54) 4.95 (4.68e5.44) 0.32
% predicted 104  15 104  14 0.47
RV, L 1.86 (1.27e2.11) 1.74 (1.43e2.12) 0.19
% predicted 127 (103e151) 127 (103e146) 0.19
RV/TLC 0.34 (0.29e0.43) 0.34 (0.29e0.42) 0.28
DLCO, mL/
min/mmHg
17.8  6.5
% predicted 68  24
Values are the mean  SD or median (25the75th percentiles).
Paired t-test or Wilcoxon test was used to compare data.
Definition of abbreviations: DLCO: diffusion capacity of the lungs
for carbon monoxide; FEV1: forced expiratory volume in the first
second; FVC: forced vital capacity; IC: inspiratory capacity; RV:
residual volume; TLC: total lung capacity.
*p < 0.05 Z statistical significance.
Table 1 Population characteristics and peak data of the
incremental cardiopulmonary exercise testing of the pa-
tients with lymphangioleiomyomatosis.a
Patients with LAM
(n Z 38)
Age, years 41  10
BMI, kg/m2 24.4  3.9
Baseline dyspnoea index 11 (9e12)
Exercise time, min 7.3 (5.4e8.2)
Work rate, W 100  26
% predicted 75  18
VO2, mL/kg/min 19.6  5.9
RER 1.23  0.14
VE/VCO2 slope 32.1 (29.7e38.4)
VE, L/min 54  16
Breathing reserve, %MVV 36  18
VT, L 1.49  0.31
f, breaths/min 37  8
HR, beats/min 151  17
% predicted 86  9
SpO2, % 96 (90e97)
Borg dyspnoea score 5 (3e8)
Borg leg discomfort score 7 (5e9)
DIC from rest, L 0.21  0.31
% 9  13
Values are the mean  SD or median (25the75th percentiles).
Definition of abbreviations: DIC: inspiratory capacity variation;
BMI: body mass index; f: respiratory rate; HR: heart rate; LAM:
lymphangioleiomyomatosis; MVV: maximal voluntary ventila-
tion; RER: respiratory exchange rate; SpO2: oxyhaemoglobin
saturation by pulse oximetry; VCO2: carbon dioxide production;
VE: minute ventilation; VO2: oxygen consumption; VT: tidal
volume.
a Data of a recent incremental cardiopulmonary exercise
testing was reviewed from a study that had already been pub-
lished [2].
1776 B.G. Baldi et al.salbutamol (400 mcg) did not reduce DH during submaximal
CPET on a cycle ergometer, and also did not increase
breathing reserve. In addition, salbutamol did not produce
significant variation in other ventilatory variables (f and
VT); there was also no significant effect on dyspnoea in-
tensity upon exercise cessation. Salbutamol treatment was
associated with a slight increase in SpO2. No significant
interaction effect between treatment period and inter-
vention was demonstrated for IC variation (F Z 0.48;
p Z 0.49), exercise time (F Z 1.1; p Z 0.3) and Borg
dyspnoea score (F Z 0.38; p Z 0.54).
Comparison between the DH and non-DH subgroups
As shown in Tables 4 and 5, we compared the PFTs and
endurance CPET data after each intervention between pa-
tients with LAM who had DH during incremental CPET
(subgroup DH) and those who did not develop DH (subgroup
non-DH).
In the PFTs (Table 4), the patients with DH were char-
acterised by airflow obstruction, air trapping and dimin-
ished DLCO, and had a slightly greater variation in FEV1, RV
and RV/TLC ratio after salbutamol in comparison with thesubgroup non-DH. However, there was no difference be-
tween the subgroups in resting IC after BD. Six patients
(32%) in the subgroup DH showed a positive response to BD
based on ATS/ERS criteria, compared with 1 patient (5%) in
the subgroup non-DH (p Z 0.09) [6].
In the evaluation of endurance CPETs after each inter-
vention, exercise time after administration of placebo was
similar, and there was no significant improvement in exer-
cise time after BD, comparing the subgroups (Table 5).
Salbutamol did not produce significant increases in isotime
IC (DH reduction) and did not lead to beneficial effects on
other ventilatory variables (isotime f, VT and breathing
reserve), even in the subgroup DH. However, there was a
greater decrease in dyspnoea intensity at exercise cessa-
tion and a slightly greater increase in SpO2 after salbutamol
in the subgroup DH.
We analysed the endpoints taking into account the
treatment with doxycycline and with hormonal blockage,
and also the prior history of pleurodesis, and there was no
difference in the results obtained (data not shown).
Responders versus non-responders to
bronchodilators
We also compared the patients with positive responses to
salbutamol, based on spirometry (responders to BD), with
patients without positive responses (non-responders to BD).
Although salbutamol produced significant increases in FEV1
and FEV1/FVC ratio, and a reduction in air trapping in the
responders to BD, there was no difference in exercise
tolerance, reduction of DH or dyspnoea intensity, or
Table 3 Comparison of submaximal endurance exercise
tests on a cycle ergometer of patients with lymphangio-
leiomyomatosis after administration of placebo or
salbutamol.
Placebo
(n Z 38)
Salbutamol
(n Z 38)
P
Exercise time, min 4.9 (3.6e6.7) 4.8 (3.7e6.8) 0.67
75% of the peak
work, W
74  20
IC (baseline), L 2.28  0.45 2.35  0.45 0.03*
% predicted 93  17 96  18 0.03*
IC (isotime), L 2.08  0.5 2.14  0.48 0.005*
% predicted 85  19 87  19 0.008*
DIC (isotime e
baseline), L
0.21  0.27 0.20  0.32 0.96
f (isotime),
breaths/min
37  8 37  8 0.51
VT (isotime), L 1.57  0.4 1.56  0.36 0.81
VE (isotime), L/min 51  13 53  15 0.1
Breathing reserve
(isotime), %MVV
41  18 40  18 0.34
VO2(maximum),
mL/kg/min
20.2  5.5 20.3  6.2 0.92
Borg dyspnoea score 5 (4e9) 5 (4e9) 0.9
SpO2 (final), % 95 (91e97) 97 (94e98) <0.001*
DSpO2 (final e
initial), %
2 (5 to 0) 0 (0e0) <0.001*
Values are the mean  SD or median (25the75th percentiles).
Paired t-test or Wilcoxon test was used to compare data.
Definition of abbreviations: DIC: inspiratory capacity variation;
DSpO2: oxyhaemoglobin saturation variation; f: respiratory
rate; IC: inspiratory capacity; MVV: maximal voluntary ventila-
tion; SpO2: oxyhaemoglobin saturation by pulse oximetry; VE:
minute ventilation; VO2: oxygen consumption; VT: tidal volume.
*p < 0.05 Z statistical significance.
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after BD (Tables 1 and 2 in the online data supplement).Discussion
To our knowledge, this is the first study that has evaluated
the effect of an inhaled short-acting BD on resting pulmo-
nary volumes and also on exercise outcomes, including in-
creases in exercise time, reversal of DH and decreases in
dyspnoea intensity, in patients with LAM. The main findings
of this study are as follows: (1) in patients with LAM, sal-
butamol improved FEV1 and reduced airflow obstruction
without causing an increase in resting IC or decrease in air
trapping; (2) salbutamol did not result in higher exercise
tolerance, a reduction in DH or an improvement in dysp-
noea or in breathing reserve during the endurance exercise
evaluation; (3) even in the patients with LAM who had DH
during incremental CPET, there was no beneficial effect on
exercise outcomes, except for a decrease in dyspnoea
intensity.
LAM is an uncommon disorder with variable progression
and no definitive treatment [1]. There is recent evidence ofbeneficial effects of mammalian target of rapamycin for a
subgroup of patients, and a potentially favourable
perspective with metalloproteinase inhibitors [26,27].
Hormonal therapy has been the most widely used treatment
for LAM, but it has controversial results [1,28]. LAM cell
proliferation around bronchioles could exert a potential
reversible bronchoconstriction, and recent guidelines sug-
gest a trial of BDs in patients with airflow obstruction [1,4].
As air trapping and DH during exercise are common findings
in LAM, BDs could also have favourable effects on these
functional changes [2]. Our patients were characterised by
airway obstruction, air trapping and decreased DLCO.
Consistent with previous studies, which showed positive
responses to BDs in 6e30% of patients, we found a signifi-
cant response to BD in 7 patients (18%) [3e8]. Taveira-
DaSilva et al. showed that a positive response to BD is
associated with a lower FEV1, and a greater predominance
of a solid pattern of LAM lesions in the lung biopsy speci-
mens, which suggests that an increase in expiratory flow
would be associated with relaxation of LAM cells by b2
adrenergic receptor agonists [4,8]. However, no previous
study investigated the BD effect on resting pulmonary vol-
umes, which may be more correlated with response in ex-
ercise outcomes than the isolated assessment of FEV1.
Although we have found statistical significance in the
FEV1 variation after BD, this difference likely has small
clinical relevance because the mean variation was only
130 mL (5%) and was not associated with increases in
resting IC or reductions in air trapping. Even when we
compared the bronchodilator response on PFTs between DH
and non-DH subgroups, the differences in FEV1 and RV/TLC
ratio variation were small (below 10%), with no difference
in the change of resting IC. The improvement in expiratory
flow was probably associated with reduction in airway
resistance, which suggests a direct relation with the use of
salbutamol. In the whole group there was an increase in
FEV1, with no increase in FVC and TLC, and a reduction in
FEV1/FVC ratio, and also in the subgroup DH there was
significant reduction in RV and in RV/TLC ratio. These
findings are different from the results of MILES trial, which
speculates that a reduction in restrictive impairment would
be a potential mechanism for the increase in airflow [26].
Although the criteria used to establish positive responses to
BD consider increases in expiratory flow, investigations in
COPD show that FEV1 variation is not a good predictor of
improvement in exercise endurance and reversal of DH. The
changes in static and dynamic pulmonary volumes, such as
IC and VT, demonstrate a better correlation with exercise
outcomes. Therefore, establishing only FEV1 as an outcome
to consider the response to BD may underestimate the
occurrence of significant clinical benefits [6,14,15,29]. Our
results are in the same line with those reported in COPD
patients, since increase in FEV1 after salbutamol was not
associated with increase in IC, even in the subgroup DH,
and there was not a consistent benefit over dynamic
hyperinflation.
Previous studies identified multiple factors for exercise
limitation in LAM, mainly ventilatory and gas exchange
abnormalities [2,11e13]. A recent study showed that the
development of DH during exercise is very prevalent in
LAM, even in patients with mild spirometric abnormalities,
and is associated with greater dyspnoea intensity, airflow
Table 4 Comparison of pulmonary function tests after administration of placebo or salbutamol between the lymphangio-
leiomyomatosis subgroups (dynamic hyperinflation versus non-dynamic hyperinflation).
Subgroup DH
(n Z 19)
Subgroup non-DH
(n Z 19)
FEV1 (after placebo), L 1.88  0.69 2.65  0.47*
% predicted 67  24 91  15*
DFEV1 after salbutamol, mL 159  172 95  127
% 10  12 4  5*
FVC (after placebo), L 3.14  0.59 3.39  0.55
% predicted 91  15 97  14
DFVC after salbutamol, mL 70 (30 to 262) 20 (97 to 80)
% 4  6 0  4*
FEV1/FVC (after placebo) 0.59  0.17 0.78  0.08*
IC (after placebo), L 2.19 (1.96e2.45) 2.4 (2.13e2.64)
% predicted 96  19 100  18
DIC after salbutamol, mL 80 (382 to 345) 40 (145 to 90)
% 4 (14 to 14) 2 (6 to 4)
RV (after placebo), L 2.11 (1.82e2.74) 1.39 (1.21e1.91)*
% predicted 161  50 111  21*
DRV after salbutamol, mL 180 [420 to (42)] 40 (15 to 150)*
% 8 [16 to (2)] 2 (1 to 12)*
RV/TLC (after placebo) 0.42  0.1 0.31  0.05*
DRV/TLC 0.03 (0.06 to 0) 0.01 (0.01 to 0.03)*
% 7 [15 to (1)] 2 (2 to 11)*
DLCO, mL/min/mmHg 12.9 (10.7e17.7) 22.1 (19.1e24.5)*
% predicted 48 (40e71) 81 (72e92)*
Values are the mean  SD or median (25the75th percentiles).
Definition of abbreviations: DFEV1: forced expiratory volume in the first second variation; DFVC: forced vital capacity variation; DIC:
inspiratory capacity variation; DRV: residual volume variation; DRV/TLC: RV/TLC ratio variation; DH: dynamic hyperinflation; DLCO:
diffusion capacity of the lungs for carbon monoxide; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; IC:
inspiratory capacity; RV: residual volume; TLC: total lung capacity.
*p < 0.05.
1778 B.G. Baldi et al.obstruction, air trapping and decreased DLCO [2]. Short- and
long-acting BDs were previously explored in COPD patients,
which produced a reversal of DH during exercise and an
increase in exercise tolerance [15,29,30]. As LAM has many
similarities in PFTs with COPD, the administration of BDs
would be a plausible option to improve these exercise
outcomes in patients with LAM.
Other studies evaluated the effect of inhaled BDs on
spirometry in patients with LAM. However, the effects on
resting pulmonary volumes and exercise outcomes were not
previously explored [3e5,7,8]. In our study, salbutamol did
not produce increases in exercise tolerance, reversal of DH,
increases in breathing reserve, or decreases in dyspnoea
intensity during endurance CPET, even in those patients
with positive responses to BD based on spirometry. These
effects, except for a reduction in dyspnoea intensity, were
not found even in the subgroup DH. Although we have found
statistical significance in the SpO2 variation at peak exer-
cise after BD, this difference likely has small clinical rele-
vance because the median variation was less than 4%.
There are several possible reasons that salbutamol did
not have beneficial effects on static lung volumes and ex-
ercise outcomes in this study. First, the presence of b2
adrenergic receptors in LAM cells has not been investigated
and as a result the absence or reduced expression of these
receptors could be a limiting factor for relaxation of LAM
cells by b2 adrenergic receptor agonists. In addition, wecould not exclude whether other classes of BDs, such as
anticholinergic agents, or long-acting b2 agonists would
affect exercise outcomes, which have already been
demonstrated in COPD patients [15,29,30]. In our study, the
patients inhaled the recommended dose of salbutamol
(400 mcg) to confirm the BD response and there was not
even a trend of improvement in resting IC or dynamic hy-
perinflation during exercise [6]. Despite the use of salbu-
tamol continuously could be an alternative intervention, it
could have resulted in even lower chance of positive
response, because it can induce tachyphylaxis to BD [31].
Therefore, although our results are robust, we could not
completely exclude a potential benefit during exercise of
inhalation of BDs for patients with LAM. Another limitation
is the exercise modality used in this study. The cycle
ergometer could have been less sensitive in achieving
maximal exercise capacity because it promotes greater
overload of lower limb muscles compared with walking and
may have caused earlier muscle fatigue. There is evidence
that walking is more sensitive to evaluate changes in
ventilatory variables and the effects of BDs on exercise
outcomes could be investigated in this modality [32].
In summary, although airflow obstruction is present and
related to more symptoms in patients with LAM, this study
shows that the positive response to salbutamol based on
FEV1, with no changes in lung volumes, does not reflect an
improvement in exercise outcomes in patients with LAM,
Table 5 Comparison of submaximal endurance exercise tests on a cycle ergometer after administration of placebo or sal-
butamol between the lymphangioleiomyomatosis subgroups (dynamic hyperinflation versus non-dynamic hyperinflation).
Subgroup DH
(n Z 19)
Subgroup non-DH
(n Z 19)
Exercise time (placebo), min 4.8 (3.3e5.6) 5.6 (3.9e7.6)
75% of the peak work, W 68 (48e88) 86 (65e93)
IC (isotime placebo), L 1.82  0.45 2.33  0.42*
% predicted 75  18 94  16*
DIC after salbutamol (isotime), L 0.08 (0.01 to 0.14) 0.08 (0.04 to 0.13)
VT (isotime placebo), L 1.4  0.36 1.74  0.38*
DVT after salbutamol (isotime), L 0.02 (0.03 to 0.12) 0.02 (0.01 to 0.07)
Breathing reserve (isotime placebo), %MVV 34  21 49  11*
DBreathing reserve after salbutamol (isotime), %MVV 0 (5 to 1) 0 (3 to 2)
VO2 (maximum), mL/kg/min 19.4  6.4 21.1  4.6
Borg dyspnoea score 8 (5e10) 4 (2e7)*
DBorg dyspnoea score after salbutamol 1  1 1  1*
SpO2 placebo (final), % 92 (84e96) 97 (95e98)*
SpO2 salbutamol (final), % 95 (93e98) 97 (96e98)
DSpO2 final (salbutamol e placebo), % 3 (1e8) 0 (0e1)
Values are the mean  SD or median (25the75th percentiles).
Definition of abbreviations: DBorg dyspnoea score: Borg dyspnoea score variation; DBreathing reserve: breathing reserve variation; DIC:
inspiratory capacity variation; DSpO2: oxyhaemoglobin saturation variation; DVT: tidal volume variation; DH: dynamic hyperinflation; IC:
inspiratory capacity; MVV: maximal voluntary ventilation; SpO2: oxyhaemoglobin saturation by pulse oximetry; VO2: oxygen consump-
tion; VT: tidal volume.
*p < 0.05.
Bronchodilator in lymphangioleiomyomatosis 1779even in those who had DH during CPET. Future studies
achieving more intense responses in bronchodilation using
other families of BDs or long-acting b2 agonists, or using
other exercise modalities may unveil which patients do
benefit of treatment with BDs in LAM.
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